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9-Month Clinical, Angiographic, and
Intravascular Ultrasound Results of a Prospective
Evaluation of the Axxess Self-Expanding Biolimus
A9-Eluting Stent in Coronary Bifurcation Lesions
The DIVERGE (Drug-Eluting Stent Intervention
for Treating Side Branches Effectively) Study
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Joseph Dens, MD, PHD,‡ John Ormiston, MD,§ Stephen Worthley, MD, Brett Trauthen, MS,¶
Takao Hasegawa, MD,# Bon-Kwon Koo, MD, PHD,# Peter J. Fitzgerald, MD, PHD,#
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Antwerp, Leuven, and Genk, Belgium; Auckland, New Zealand; Adelaide, Australia;
Lake Forest and Stanford, California; and New York, New York
Objectives This study sought to assess the safety and performance of the Axxess (Devax Inc., Lake Forest, California) self-
expanding drug-eluting stent in coronary bifurcation lesions.
Background Percutaneous treatment of coronary bifurcations is a predictor of adverse late outcomes, in part because of the
lack of dedicated devices.
Methods Patients with de novo bifurcation lesions were prospectively enrolled in a multicenter study. The Axxess stent was
deployed at the level of the carina followed by additional sirolimus-eluting stents in the distal parent vessel (PV)
and/or side branch (SB). All patients underwent clinical follow-up at 9 months; 150 were to receive control angiogra-
phy and 76 were to receive intravascular ultrasound. The primary end point was the rate of major adverse cardiac
events (MACE): a composite of death, myocardial infarction (MI), and target lesion revascularization (TLR). Secondary
end points included in-segment restenosis, late loss, and percent neointimal volume obstruction.
Results Overall, 302 patients were treated with 299 Axxess stents (99%). Additional stenting of 1 branch was performed
in 21.7% of patients (17.7% PV, 4% SB), and of both branches in 64.7%. At 9 months, 99.3% of patients re-
turned for clinical follow-up; from the angiographic and IVUS substudies, 93.3% and 89.4% returned. The cumu-
lative 9-month MACE rate was 7.7% (0.7% death, 3.3% non–Q-wave MI, 1.0% Q-wave MI, 4.3% TLR). Subacute
and late stent thrombosis occurred in 0.7% and 0.3% of patients. Total restenosis was 6.4% (3.6% PV, 4.3% SB),
late loss was 0.20  0.41 mm in the PV and 0.17  0.34 mm in the SB. In the Axxess stent segment, percent
neointimal volume obstruction was 4.3  5.2%.
Conclusions This prospective multicenter study confirms the safety and performance of the Axxess stent in bifurcation lesions.
(Drug-Eluting Stent Intervention for Treating Side Branches Effectively; ACTRN12606000259549)
(J Am Coll Cardiol 2009;53:1031–9) © 2009 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2008.12.012a
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Self-Expanding Biolimus Stent in Bifurcations March 24, 2009:1031–9when compared with mid-vessel
lesions (2,3). This is mainly be-
cause of suboptimal results in the
side branch (SB). Despite the im-
plementation of numerous tech-
niques (T-stenting, V-stenting,
kissing-balloon stenting, crush
stenting, culotte stenting) to stent
both branches, none of them, even
in the drug-eluting stent era, has
shown clinical and angiographic
superiority to the single parent
vessel (PV) stent technique with
provisional T-stenting of the SB
in case of dissection or residual
severe disease (4–6).
Novel dedicated stents have
recently been developed to pro-
vide easier access to the SB and
o scaffold more effectively its ostium, matching the stent
onfiguration more closely to the anatomy of the bifur-
ation. However, clinical data on these devices are still
parse (7).
The Axxess stent (Devax Inc., Lake Forest, California)
elongs to this category of dedicated bifurcation lesion
tents (8). It is a self-expanding drug-eluting stent, deployed
t the level of the carina, which provides easy access to the
istal branches that subsequently can be provisionally
reated with percutaneous coronary intervention (PCI),
epending on the disease status of these branches. The
ationale behind this stent is to provide an anatomically
ailored treatment of the bifurcation with maximum drug
overage and minimum overlap or deformation of the stent
truts. The Axxess stent has been previously tested in
linical practice in the prospective multicenter Axxess Plus
egistry enrolling 139 patients, in whom, together with the
xxess stent, sirolimus- or paclitaxel-eluting stents were
sed as additional stents to optimize the procedure. The SB
reatment was left at operator discretion, and stenting of the
B was performed in approximately one-half of the lesions.
ost hoc analysis of lesions treated with stent deployment in
he SB provided better procedural outcomes and better late
esults with 10% restenosis of the SB, compared with
20% SB restenosis after balloon-only angioplasty (9).
The current study was planned to expand these results in
broader population, keeping stricter protocol obligations
or lesion treatment, such as the mandated use of sirolimus-
luting stents as additional stents for the PV and the SB if
he residual diameter stenosis exceeded 30%.
ethods
he DIVERGE (Drug Eluting Stent Intervention for
reating Side Branches Effectively) study is a prospective
ulticenter registry. The local ethics committee of every
Abbreviations
and Acronyms
IVUS  intravascular
ultrasound
MACE  major adverse
cardiac event
MI  myocardial infarction
MLD  minimal luminal
diameter
PCI  percutaneous
coronary intervention
PV  parent vessel
RVD  reference vessel
diameter
SB  side branch
TLR  target lesion
revascularizationospital participating in the study approved the study eesign. All enrolled patients provided written informed
onsent before the index procedure.
atient population. The study population consisted of
ale and female patients, 18 to 80 years of age, with
ocumented stable or unstable angina or positive functional
tudy, identified for elective PCI of a de novo native
oronary artery bifurcation lesion in a major coronary artery
n which either the PV or the SB had at least a 50%
iameter stenosis. The RVD by visual estimate had to be
.75 to 3.75 mm in the PV and 2.25 mm in the SB. The
esion length had to be 25 mm in the PV, with 10 mm
roximal to the carina. The SB ostium needed to be located
12 mm from the left main coronary artery. The angle
etween the distal PV and the SB had to be 70°. The
rotocol allowed concurrent treatment of 1 additional le-
ion, provided it was located in a different primary epicardial
essel and was successfully treated before the bifurcation
esion.
Clinical exclusion criteria were: pregnant female; myocar-
ial infarction (MI) within the previous 72 h; cardiogenic
hock; creatine kinase level above the upper limit of nor-
ality at the time of the procedure; documented left
entricular ejection fraction 30%; cerebrovascular accident
r gastrointestinal/genitourinary bleeding within the past 6
onths; renal insufficiency (creatinine 2.0 mg/dl); throm-
ocytopenia (platelet count 105/mm3); anemia (hemoglo-
in 10 g/dl); current or planned use of oral anticoagulant
gents; contraindications to aspirin, clopidogrel, heparin, or
ontrast agents; known sensitivity to sirolimus, stainless
teel, titanium, nickel; life expectancy 2 years; or current
articipation in another investigational drug or device study.
ngiographic exclusion criteria were: previous PCI in the
arget vessel9 months from the index procedure; left main
tenosis; severe calcification, excessive tortuosity, or pres-
nce of intraluminal thrombus by visual estimation; and
re-treatment of the target lesion with any unapproved
evice or atherectomy or laser (cutting balloon was allowed).
tudy device. The Axxess stent is made from a nickel-
itanium alloy (nitinol) in the austenitic (superelastic) phase.
he stent elutes Biolimus A9 (Biosensors International,
td., Newport Beach, California), a derivative of sirolimus,
ith similar antiproliferative properties (10). Drug release is
ediated by a bioabsorbable polylactic acid-based polymer
which is metabolized over time into carbon dioxide and
ater). This drug-polymer coating is applied to the ablu-
inal surface of the stent. The nominal drug loading is 22
g/mm of stent length for all sizes.
The procedure for stent placement typically requires
iring of both branches of the lesion, followed by successful
re-dilation of the PV and the SB to provide space for the
elf-expanding stent. The stent is kept in place on the
elivery system by a covering sheath, which is clearly visible
nder fluoroscopy. The stent is deployed by gently retract-
ng the sheath once the stent is in place at the level of the
arina. The stent has 1 radiopaque marker at the proximal
dge and 3 markers at the distal edge to assist in accurate
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March 24, 2009:1031–9 Self-Expanding Biolimus Stent in Bifurcationsositioning and deployment at the target site (Fig. 1). The
xxess stent’s conical shape and self-expanding property
llow it to cover the irregular anatomy of a bifurcation at the
evel of the carina up to bifurcation angles of 70°. The stent
s unique in that it spans both the PV and the SB without
bstructing access to either, and allows easy passage of
dditional stents in both branches. If needed, additional
tents are implanted to complete lesion coverage. Accurate
istal stent position is aided by the presence of the distal
arkers on the Axxess stent. In this study a small amount (1
Figure 1 Fluoroscopic Image Showing Partially Deployed
Stent Position Within Bifurcation Lesion
Stent (thin arrows) and cover sheath (thick arrow) markers are clearly visible.
A
Figure 2 Final Placement Angiogram
(A) Contrast-filled angiogram shows the Axxess stent in the proximal left anterior d
the mid-LAD and 2 markers in the diagonal branch) and an additional Cypher in th
visualization.o 2 mm) of overlap was targeted. Post-dilation focus is on
he distal branch stents, with attention to ensure full
eployment at the overlap segments. Because the branch
essel stents are implanted distal to the carina, flow to the
B is unobstructed, and no strut deformation is induced by
ost-dilation (Fig. 2).
rocedural protocol and follow-up. After percutaneous
ccess was obtained, heparin was administered to maintain
n activated clotting time250 s (or200 s if glycoprotein
Ib/IIIa inhibitors were given). Eligible patients underwent
andatory pre-dilation of the PV and, at operator’s discre-
ion, of the SB. At this point, placement of the Axxess
elf-expanding stent at the site of the bifurcation was
erformed. The stent diameters available for the study were
.0 and 3.5 mm, with lengths of 11 or 14 mm. All patients
ho had the study stent introduced into the vasculature
ere considered enrolled in the DIVERGE study. Depend-
ng on the disease status of the distal PV and distal SB,
djunctive stenting, in overlap of the distal edge of the
xxess stent and extending into the branch vessels, was
ermitted. An optimal angiographic outcome was strongly
ecommended to obtain no residual stenosis at the end of
he procedure. Thus, additional stents were implanted if
here was a residual stenosis of 30% in any segment of the
ifurcation. The protocol mandated the use of Cypher
irolimus-eluting stents (Cordis, Johnson & Johnson, War-
en, New Jersey) for this purpose. Bail-out stenting with
dditional Cypher stents was allowed in case of dissection or
ncomplete lesion coverage. The first 150 patients enrolled
ere allocated into an angiographic substudy, whereas the
rst 76 patients at selected sites were allocated into an
ding artery (LAD) (left anterior oblique artery view with 1 marker at the level of
AD. (B) Stent boost image shows an enhanced contrast-negative stentB
escen
e mid-L
i
a
a
u
A
(
t
f
o
p
A
C
d
c
t
a
p
r
a
o
Q
D
i
e
L
a
i
c
g
i
p
d
m
d
w
M
p
s
t
b
M
d
a
r
t
o
s
C
s
m
s
b
q
e
o
b
I
s
v
a
E
s
a
c
a
S
n
s
e
o
l
c
c
r
o
p
r
c
a
i
s
p
d
c
n
t
c
(
f
p
s
t
b
t
s
e
a
c
P
A
c
r
o
a
a
p
I
1034 Verheye et al. JACC Vol. 53, No. 12, 2009
Self-Expanding Biolimus Stent in Bifurcations March 24, 2009:1031–9ntravascular ultrasound (IVUS) substudy. The IVUS ex-
mination was performed at the end of the procedure
ccording to standard protocols using a 20 to 40 MHz
ltrasound probe with motorized pullback (speed: 0.5 mm/s).
spirin (80 mg/day) was given daily and clopidogrel
loading dose of at least 300 mg before or immediately after
he procedure and 75 mg/day thereafter) was administered
or at least 6 months in all patients. A protocol amendment
f October 2007 mandated clopidogrel for 12 months
ost-procedure according to the updated American Heart
ssociation/American College of Cardiology/Society for
ardiovascular Angiography and Interventions recommen-
ations (11). Serial blood samples for creatine kinase and
reatine kinase-MB were routinely obtained 8 and 16 h after
he intervention.
Patients were evaluated clinically at 1, 6, and 9 months
fter the procedure. Control angiography and IVUS were
erformed after the 9-month visit, or earlier if there were
ecurrent symptoms. If restenosis was not found in an
ngiography performed 4 months post-procedure, a sec-
nd angiography was done at 9 months.
uantitative coronary angiography and IVUS analysis.
igital coronary angiograms were analyzed offline by an
ndependent core laboratory, using a validated automated
dge detection system (QAngioXA version 7.1.14.0, Medis,
eiden, the Netherlands). Matched views were selected for
ngiograms recorded before and immediately after the
ntervention and at follow-up. Bifurcation lesions were
lassified according to the Medina classification (12). An-
iographic measurements were made both in the stent and
n the stented segment (defined as the whole stented tract
lus the 5-mm edges proximal and distal to the stent)
uring diastole using the contrast-filled guiding catheter for
agnification calibration. Lesion RVD, minimal luminal
iameter (MLD), percent diameter stenosis, and length
ere obtained at baseline for both the PV and the SB. The
LD and diameter stenosis were evaluated at the end of the
rocedure and at follow-up for the in-segment and -stent
ections in both the PV and the SB, and specifically only for
he Axxess stent. Acute gain was defined as the difference
etween the MLD at the end of the intervention and the
LD at baseline. Late lumen loss was calculated as the
ifference in MLD between measurements immediately
fter the procedure and at follow-up. Binary angiographic
estenosis was defined as diameter stenosis 50% by quan-
itative coronary angiography at the follow-up angiogram.
Quantitative and qualitative IVUS analyses were performed
ffline by an independent core laboratory using validated
oftware (echoPlaque, INDEC Medical Systems, Santa Clara,
alifornia), allowing semi-automated detection of luminal and
tent boundaries in reconstructed longitudinal planes. Volu-
etric quantitative IVUS analysis was obtained for vessel,
tent, and lumen. Serial volumetric measurements were done if
aseline and follow-up runs were matched and of adequate
uality. Neointimal volume index was computed as the differ-
nce between stent volume and lumen volume per millimeter sf stent. Percent volume obstruction was calculated as the ratio
etween the neointimal volume and stent volume  100.
ncomplete stent apposition was defined as 1 or more stent
truts clearly separated from the vessel wall with evidence of a
oid behind the strut in a vessel segment not associated with
ny SBs.
nd points and definitions. The primary end point of the
tudy was the rate of major adverse cardiac events (MACE)
t 9 months; MACE were defined as any of the following:
ardiac or noncardiac death, Q-wave or non–Q-wave MI,
nd ischemia-driven target lesion revascularization (TLR).
econdary angiographic end points included binary reste-
osis and late lumen loss, evaluated in-segment, in the
tented area, and in the Axxess stent only. Secondary IVUS
nd points were neointimal tissue volume, percent volume
bstruction within the study device, and incidence of
ate-acquired stent incomplete apposition and strut tissue
overage at 9 months. Cardiac death was defined as death
aused by acute MI, congestive heart failure, cardiac perfo-
ation, arrhythmia, cerebrovascular accident within 30 days
f the index procedure, or complication of the index
rocedure (including bleeding, vascular repair, transfusion
eaction, or bypass surgery) or any death in which a cardiac
ause could not be excluded. Noncardiac death was defined
s a death not attributable to cardiac causes. Myocardial
nfarction was defined as: 1) Q-wave MI when chest pain or
ymptoms consistent with myocardial ischemia and new
athological Q waves in 2 or more contiguous electrocar-
iograph leads were present; and 2) non–Q-wave MI if
reatine kinase was elevated 2 the upper laboratory
ormal with the presence of elevated creatine kinase-MB in
he absence of new pathological Q waves. The TLR was
onsidered ischemic, defined as repeat revascularization
PCI or bypass surgery) in the presence of a positive
unctional study for ischemia because of restenosis of any
ortion of the target lesion, or TLR of a 70% diameter
tenosis anywhere within the target lesion. In this study, the
arget lesion was defined as any treated segment of the
ifurcation—PV or SB—plus a border of 5 mm. Stent
hrombosis was defined according to the Academic Re-
earch Consortium criteria (13). An independent clinical
vents committee adjudicated all of the clinical events, and
n independent data safety monitoring board reviewed
linical data periodically throughout the study.
In addition, several procedure parameters were assessed.
rimary device success was defined as deployment of the
xxess stent without system failure or device-related compli-
ation. Lesion success was defined as attainment of 50%
esidual stenosis of the target lesion using the assigned device
r any percutaneous method. Procedure success was defined as
ttainment of a final lesion (angiographic) success in the
bsence of any in-hospital MACE. Finally, Axxess stent
lacement was evaluated independently by the core laboratory.
t was considered accurate if 1 of the 3 distal markers of the
tent was clearly in each of the PV and SB, respectively, or if

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March 24, 2009:1031–9 Self-Expanding Biolimus Stent in Bifurcations2 markers were in the triangle formed by the carina and the
stia of the branch vessels.
tatistical analysis. All analyses were conducted according
o the intention-to-treat principle. Continuous data are
xpressed as mean  SD or as median [interquartile
anges], as appropriate, whereas dichotomous data are
ummarized as frequencies.
esults
etween June 2006 and October 2007, 302 patients were
nrolled in the DIVERGE study (Fig. 3).
tudy population and the procedural and in-hospital
utcomes. Baseline clinical characteristics of the patients
re shown in Table 1, whereas the angiographic and
rocedural characteristics of the lesions treated are pre-
ented in Tables 2 and 3. A majority of the lesions were
ategorized as true bifurcations (77.4%) and had presence of
isease in the SB (78.1%) according to the Medina classi-
cation system. At baseline, mean lesion length and RVD
y quantitative coronary angiography were 14.6 and 2.93
m, respectively, in the PV, and 6.9 and 2.3 mm in the SB.
The Axxess stent was placed in 299 of 302 patients
99.0%). The placement was scored as optimal by the
ngiographic core laboratory in 93% of cases. In 3 patients,
he Axxess stent was withdrawn because of anatomical
onfigurations outside of the study inclusion criteria. In 2
dditional cases, the Axxess stent was not placed at the
ifurcation, thus primary device success was obtained in 297
f 302 patients (98.3%). These lesions were successfully
reated with other techniques.
Additional stents were placed in the distal branch vessels
epending on disease distribution, resulting in the patterns
hown in Figure 4. In keeping with the prevalence of diseased
Bs in this study, the most frequent treatment pattern was for
Enrollment 
N=302
1 Month 
Office Visit (N=302)
6 Months 
Check up (N=302)
9 Months
Primary Endpoint
Clinical Evaluation 
N=300 (99% FU)
Angiography 
N=140 (93% FU)
IVUS Evaluation
N=68 (89% FU)
Figure 3 Flow Diagram of Subjects’ Progress
Through Phases of the DIVERGE Study
DIVERGE  Drug-Eluting Stent Intervention for Treating Side
Branches Effectively; FU  follow-up; IVUS  intravascular ultrasound.oth branch vessels to be stented (64.7%), but in several cases
a
oaseline Characteristics of the Patients Enrolled
Table 1 Baseline Characteristics of the Patients Enrolled
Patients (n  302)
Age (yrs) 62.8 10.6
Male sex 224 (74.2%)
Body mass index (kg/m2) 27.5 4.1
Diabetes mellitus 55 (18.2%)
Insulin-dependent 17 (5.6%)
Hypertension 171 (56.6%)
Hypercholesterolemia 236 (78.1%)
Current smoker 71 (23.5%)
Prior myocardial infarction 88 (29.1%)
Prior percutaneous intervention 96 (31.8%)
Prior bypass surgery 7 (2.3%)
Unstable angina 71 (23.5%)
Ejection fraction (%) 68.4 11.1
Glycoprotein IIb/IIIa inhibitors 36 (11.9%)
ata are presented as numbers (percentages) or means  SDs, unless otherwise specified.aseline Characteristics of the Lesions Enrolled
Table 2 Baseline Characteristics of the Lesions Enrolled
Lesions (n  302)
Target vessel
Left anterior descending/diagonal 244 (80.8%)
Circumflex/obtuse marginal 44 (14.6%)
Right coronary artery/posterior descending 14 (4.6%)
Medina classification of the bifurcation
1,0,0 20 (6.6%)
1,1,0 36 (12%)
1,0,1 20 (6.6%)
1,1,1 194 (64.5%)
0,1,1 19 (6.3%)
0,1,0 10 (3.3%)
0,0,1 2 (0.7%)
True bifurcation lesion (1,0,1 or 1,1,1 or 0,1,1) 234 (77.4%)
Angle between branches (°) 54.2 24.9
Post-dilation 259 (85.8%)
Mean inflation pressure (atm) 12.5 3.2
Mean balloon size (mm) 2.70 0.29
Proximal main branch 2.78 0.37
Distal main branch 2.55 0.32
Side branch 2.76 0.37
Total number of stents implanted 804
Total stent length (mm) 37.8 14.7
Axxess stent without distal stents 37 (12.3%)
Axxess and distal main branch stents 53 (17.7%)
Axxess and distal side branch stents 12 (4.0%)
Axxess and stent in both branches 194 (64.7%)
Axxess stent/imaging not assessible 6 (2.0%)
Axxess stents placed 299 (99%)
Device success 297 (98.3%)
Lesion success 300 (99.3%)*
Procedure success 292 (96.7%)
Optimal Axxess placement 278/299 (93%)
In 1 patient there was a total occlusion of the side branch because of untreatable dissection. In
second patient (in whom the Axxess stent was not implanted), there was a residual stenosis at the
stium of the side branch 50% after balloon angioplasty (the vessel was not stented).
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Self-Expanding Biolimus Stent in Bifurcations March 24, 2009:1031–9ingle distal stents were placed in the PV (17.7%) or the SB
4.0%). Post-dilation was performed in 85.8% of cases to a
ean inflation pressure of 12.5  3.2 atm.
Lesion (angiographic) success was obtained in 300 of 302
atients (99.3%). No deaths, TLR, or stent thrombosis
ccurred during hospitalization. The rate of periprocedural
on–Q-wave MI was 3.0%, accounting for all in-hospital
ACE. One of these was caused by periprocedural occlu-
ion of the nonstented SB, because of untreatable dissection.
hus, the procedure success rate was 96.7%.
0-day and 9-month clinical outcomes. Clinical events are
resented in Table 4. Between the end of the hospitalization
nd the first month after treatment, subacute stent thromboses
esulted in 2 Q-wave MIs (both occurring on day 4 after the
uantitative Coronary Angiography Analysis of the Lesions Treated
Table 3 Quantitative Coronary Angiography Analysis of the Les
All Patie
Parent Vessel
Pre-procedure
Reference vessel diameter (mm) 2.93 0.37
MLD (mm) 0.87 0.38
Diameter stenosis (%) 70.6 11.8
Lesion length (mm) 14.6 6.3
Post-procedure
In-segment
MLD (mm) 2.33 0.37
Diameter stenosis (%) 22.2 7.9
Acute gain (mm) 1.47 0.46
In-stent
MLD (mm) 2.69 0.35
Diameter stenosis (%) 9.6 9.1
Acute gain (mm) 1.88 0.41
Axxess only
MLD (mm) 3.10 0.41
Diameter stenosis (%) 5.7 5.5
Follow-up
In-segment
MLD (mm) —
Diameter stenosis (%) —
In-stent
MLD (mm) —
Diameter stenosis (%) —
Axxess only
MLD (mm) —
Diameter stenosis (%) —
Late loss (mm)
In-segment —
In-stent —
Axxess only —
Binary angiographic restenosis
In-segment —
In-stent —
Axxess only —
In-segment bifurcation restenosis —
In-stent bifurcation restenosis —
ata are presented as mean  SD or n (%).
MLD  minimal luminal diameter.ndex procedure and under double antiplatelet therapy). Both aatients underwent urgent percutaneous revascularization, but
event was fatal. There was 1 ischemia-driven TLR, so that
he overall rate of 1-month MACE was 4.0%. At 9 months,
linical follow-up was available in 300 patients (99.3%). Two
atients withdrew consent for further follow-up at 6 months: 1
as event-free, whereas the other experienced a TLR after 3
onths. The cumulative 9-month MACE rate was 7.7%,
ncluding 0.7% death, 4.3% MI, and 4.3% TLR. Between 1
nd 9 months, 1 cardiac death was recorded at 8 months in a
atient who underwent elective bypass surgery (with proven
n-stent restenosis of both the PV and the SB and additional de
ovo coronary lesions). One Q-wave MI, caused by late stent
hrombosis, occurred in a patient 7 months after the index
rocedure, 1 month after clopidogrel discontinuation. An
e Total Cohort and in the Angiographic Subgroup
Treated in the Total Cohort and in the Angiographic Subgroup
Angiographic Subgroup
Side Branch Parent Vessel Side Branch
2.30 0.35 2.90 0.32 2.29 0.34
1.02 0.58 0.80 0.29 0.97 0.59
55.8 22.8 72.4 9.0 57.8 23.5
6.9 3.1 14.3 6.1 6.9 3.6
2.01 0.39 2.29 0.33 1.99 0.38
18.0 9.3 22.6 8.2 18.8 9.6
0.98 0.60 1.49 0.39 1.01 0.63
(n 112)
2.44 0.33 2.68 0.31 2.41 0.34
2.1 6.7 9.2 9.2 2.5 6.9
1.60 0.44 1.89 0.39 1.64 0.44
— 3.08 0.40 —
— 6.7 5.4 —
— 2.10 0.49 1.82 0.46
— 27.5 13.8 22.7 14.9
— 2.41 0.56 2.14 0.54
— 17.0 16.6 10.5 19.0
— 2.91 0.60 —
— 0.8 18.4 —
— 0.20 0.41 0.17 0.34
— 0.29 0.50 0.29 0.45
— 0.18 0.49 —
— 5 (3.6%) 6/140 (4.3%)
— 3 (2.3%) 5/105 (4.8%)
— 1 (0.7%) —
— 9/140 (6.4%)
— 7/140 (5%)in th
ions
ntsdditional non–Q-wave MI was caused by iatrogenic total
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March 24, 2009:1031–9 Self-Expanding Biolimus Stent in Bifurcationscclusion of the distal target vessel during the planned
-month control angiography and IVUS (which showed a
ood result of the index PCI) because of embolization of
hrombotic material from the guiding catheter. Both patients
ere successfully treated with PCI. Finally, there were 8
dditional percutaneous TLRs, all with proven restenosis (1
ccurred in a patient who did not receive the Axxess stent, but
ather a bare metal stent). Of interest, among the total 13 cases
f TLR, 6 (46.1%) were PV restenoses (with or without
nvolvement of the SB), 4 (30.8%) were driven exclusively by
B restenosis, and 3 (23.1%) were stent thromboses.
uantitative coronary angiography and IVUS outcomes.
f the 150 patients included in the angiographic substudy,
40 (93.3%) received the planned control angiogram. An-
iographic data are presented in Table 3. In-bifurcation
estenosis occurred in 9 patients (6.4%): 2 patients had
estenosis in both the PV and the SB (1 total occlusion
tarting just before the Axxess stent and 1 multifocal
estenosis in 2 sites, 1 proximal to the Axxess stent and 1 in
he SB stent), 3 patients had PV restenosis (1 proximal to
he Axxess stent, and 2 in the PV stent after the bifurca-
ion), 4 patients had SB restenosis (including also the
atient with the total occlusion of the nonstented SB
ausing a periprocedural MI at baseline).
Of the 76 patients included in the IVUS substudy, 68
89.4%) received the planned control IVUS. Baseline and
ollow-up 3-dimensional volumetric analyses were available
or the Axxess stent in 54 and 56 patients, respectively. Of
he 68 follow-up patients, serial 3-dimensional analysis for
A B
C D
Figure 4 Deployment Patterns Observed in the DIVERGE Study
DIVERGE  Drug-Eluting Stent Intervention for Treating Side Branches Effectively;he Axxess stent was available in 51 patients, and serial sualitative analysis for incomplete stent apposition was
ossible in 62 Axxess stents.
The IVUS data are presented in Table 5. Follow-up
eointimal hyperplasia obstruction within the Axxess stent
n terms of percent of stent volume was 4.3  5.2%. The
elf-expanding Axxess stent increased in mean volume index
rom the procedure to follow-up from 7.4  2.0 mm3/mm
o 9.6 2.6 mm3/mm of the stent, leading to a net increase
n lumen volume index from 7.3  2.0 mm3/mm to 9.2 
.5 mm3/mm.
iscussion
he use of the Axxess Biolimus-eluting stent for the treatment
f complex bifurcation lesions resulted in a high procedure
uccess rate (96.7%), a low all-cause cumulative 9-month
ACE rate (7.7%, including 3.0% periprocedural non–Q-
ave MI), and a low 9-month TLR rate (4.3%). Systematic
ngiographic follow-up of 140 patients showed an overall
n-segment restenosis rate of 6.4% inclusive of both PV and
B. The IVUS analysis showed marked suppression of neoin-
imal hyperplasia within the stent and a significant increase in
umen volume over time within the Axxess stent. In addition,
here are several methodological strengths in this study that
einforce the validity of the results obtained: prospective
nrollment, multicenter setting, total and independent moni-
oring of data acquisition, independent evaluation of the
vents, enrollment of one of the largest published cohorts of
atients with bifurcation lesions, and focus on a drug-eluting
arent vessel; SB  side branch.PV  ptent specifically dedicated for bifurcations.
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Self-Expanding Biolimus Stent in Bifurcations March 24, 2009:1031–9The design of the Axxess stent allows conformability of
he stent to the vessel wall without deformation of the struts
nd with easy access to both branches for additional PCI.
he placement technique is novel, and requires thorough
re-dilation and careful attention to marker position within
he bifurcation for optimal positioning. In this study,
ptimal placement was obtained in 93% of patients. Of the
uboptimal placements, a successful angiographic outcome
as obtained in all cases.
The advantage of this technique is that additional stents can
e placed in either or both distal segments provisionally,
epending on angiographic appearance, without distortion
rom their cylindrical shape. This allows the length and
iameter of distal stents to be selected for a precise fit to the
esion. Because the Axxess stent covers the ostium of the
ranch vessels, distal stents are placed at or slightly distal to the
arina, thus eliminating ostial stent strut obstruction and
inimizing stent strut overlap. Thus, techniques used to
ompress or distort obstructing stent struts in other bifurcation
echniques, such as kissing-balloon dilation, are eliminated.
omparison with the current evidence. Despite the fact
n-Hospital, Cumulative 30-Day,nd Cumu ative 9-Month Clinical Events
Table 4 In-Hospital, Cumulative 30-Day,and Cumulative 9-Month Clinical Events
All Patients
Angiographic
Subgroup
In-hospital (n 302) (n 150)
MACE 9 (3%) 5 (3.3%)
MI (all non–Q-wave periprocedural) 9 (3%) 5 (3.3%)
30-day (n 302) (n 150)
MACE 12 (4%) 7 (4.7%)
Death (cardiac) 1 (0.3%) 1 (0.7%)
MI 11 (3.6%) 6 (4%)
Q-wave 2 (0.7%) 1 (0.7%)
Non–Q-wave 9 (3%) 5 (3.3%)
TLR (percutaneous) 3 (1%) 2 (1.3%)
Early stent thrombosis 2 (0.7%) 1 (0.7%)
9-month (n 300) (n 149)
MACE 23 (7.7%) 14 (9.4%)
Death 2 (0.7%) 1 (0.7%)
Cardiac death 2 (0.7%) 1 (0.7%)
MI 13 (4.3%) 8 (5.4%)
Q-wave 3 (1%) 2 (1.3%)
Non–Q-wave 10 (3.3%) 6 (4%)
TLR 13 (4.3%) 8 (5.4%)
Percutaneous 12 (4%) 8 (5.4%)
Bypass surgery 1 (0.3%) 0
Stent thrombosis by Academic Research
Consortium criteria
3 (1%) 2 (1.3%)
Early (probable/possible) 0 0
Early (definite) 2 (0.7%) 1 (0.7%)
Late (probable/possible) 0 0
Late (definite) 1 (0.3%) 1 (0.7%)
Remote target vessel revascularization 19 (6.3%) 11 (7.4%)
Target vessel failure 29 (9.7%) 17 (11.4%)
ata are presented as n (%).
MACE  major adverse cardiac events; MI  myocardial infarction; TLR  target lesion
evascularization.hat there is no firm agreement on the standard treatment of Difurcation lesions, there is some consensus that a strategy
ased on single stenting of the PV with provisional stenting of
he SB is recommended; however, neither an advantage nor a
isadvantage of stenting both branches has ever been shown.
There are a few studies comparing simple and complex
trategies for bifurcation lesions. The NORDIC trial com-
ared a single PV sirolimus-eluting stent strategy (with
issing-balloon angioplasty of the SB only if the flow was
mpaired, but not if there was a residual angiographically
evere lesion) to a strategy of stenting both the PV and the
B with sirolimus-eluting stents (in this case different
echniques were allowed). This trial showed good clinical
esults, with low 6-month TLR rates in both arms (1.9% in
he PV stent arm and 1% in the PV  SB stent arm), not
nfluenced by the angiographic follow-up, performed on
urpose at 8 months. However, the overall MACE rates
valuated at 6 months (2.9% in the PV stent arm and 3.4%
n the PV  SB stent arm) did not include the periproce-
ural MI, which were as high as 8% in the PV stent group
nd 18% in the PVSB stent group. Moreover, post-
rocedural blood samples for myocardial enzymes were not
vailable in the whole cohort, but only in around 68% of the
atients, thus a risk of underestimation of the event rate
hould also be considered. Furthermore, the angiographic
estenosis rate, evaluated at 8 months, remained elevated in
oth groups (22.5% in the PV stent group and 16% in the
V SB stent group), mainly driven by the SB restenosis (4).
Another single-center trial compared the single PV
irolimus-eluting stent technique (with mandated kissing-
alloon stenting in all patients) and the routine T-stenting
echnique also with sirolimus-eluting stents, still showing
-year MACE rates of 12.9% and 11.9%, respectively, and
-month restenosis rates of 12.5% and 13.5%, respectively (6).
In general, according to these trials, no major differences
ere noted if balloon-only angioplasty or stenting were per-
ormed in the SB, and the angiographic restenosis rate still
emained above 10% with all of the techniques used. A general
eakness of these studies is that a specific strategy for the SB
reatment was mandated by the protocol, rather than by vessel
iameter or presence of disease. On the contrary, the first-
n-man Axxess Plus study, despite its nonrandomized design,
erial Intravascular UltrasoundAnalysi of Lesions Treated
Table 5 Serial Intravascular UltrasoundSerial Analysis of Lesions Treated
Post-Procedure Follow-Up
Vessel volume index (mm3/mm) 17.0 3.6 18.9 3.7
Axxess volume index (mm3/mm) 7.4 2.0 9.6 2.6
Lumen volume index (mm3/mm) 7.3 2.0 9.2 2.5
Neointimal volume index (mm3/mm) — 0.4 0.6
Total neointimal volume (mm3) — 2.1 [1.0–6.2]
Percent volume obstruction (%) — 4.3 5.2
Incomplete stent apposition (Axxess stent) 22 (35.5%) 17 (27.4%)
Persistent — 16 (25.8%)
Late acquired — 1 (1.6%)ata are presented as mean  SD, median [interquartile range], or n (%).
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March 24, 2009:1031–9 Self-Expanding Biolimus Stent in Bifurcationsuggested improved angiographic outcomes in the SB if it was
reated with a drug-eluting stent (with a restenosis rate of
.9%) as compared with balloon angioplasty (with a restenosis
ate of 25%) (9). However, stenting of the SB in the Axxess
lus study occurred only in one-half of the cohort enrolled. In
he DIVERGE study, stents were used to obtain an optimal
ngiographic result in the bifurcation in the same way as would
e done for a midvessel lesion. Using this approach, a single
xxess stent was used in 12% of lesions, an additional stent was
dded in 21.5% of lesions, and a stent was added to both
ranches is 65% of lesions. The rationale behind this approach
as to cover any diseased part of the bifurcation with both
tent and drug and to obtain an angiographically optimal
utcome at the end of the procedure. This strategy resulted in
TLR rate of 4.3%, a total bifurcation restenosis rate of 6.4%,
nd a SB restenosis rate of 4.3%.
Despite the use of multiple stents to obtain complete
overage of the lesion in the bifurcation (seen until now as a
ossible risk factor for stent thrombosis [5]), the Axxess
trategy may offer beneficial effects in terms of low stent
hrombosis rate as was seen in this study: subacute and late
tent thrombosis rates according to Academic Research Con-
ortium definitions were 0.7% and 0.3%, respectively (13). One
echanistic explanation could be the combination of the
elf-expanding properties of the study device with local drug
elivery resulting in a large proximal PV lumen, coupled with
ack of strut deformation, minimization of stent overlap, and
ndisturbed flow into the distal branch vessels.
Thus, it seems that dedicated stenting technology for
ifurcation lesions in combination with site-specific drug
elivery offers an excellent outcome in terms of clinical,
ngiographic, and IVUS end points. Based on these find-
ngs, there seems to be no penalty for stenting the SB, but
t remains to be seen in a randomized manner whether this
trategy is superior to provisional stenting.
Limitations of the technique are the angulation (70°
ngulation should be avoided) and the use of multiple stents
which may also be advantageous given the results), yet
ngiographic analysis did not show any increase of resteno-
is at overlapping stent segments.
tudy limitations. The major limitation of this study is the
ingle-arm, nonrandomized setting. Despite the encourag-
ng results shown in the DIVERGE study, a randomized
rial is warranted to prove the angiographic and clinical
uperiority of the Axxess stent versus current bifurcation
tenting techniques. Ieprint requests and correspondence: Dr. Stefan Verheye, Ant-
erp Cardiovascular Institute Middelheim, Ziekenhuis Netwerk
ntwerpen, Lindendreef 1, 2020 Antwerp, Belgium. E-mail:
tefan.verheye@telenet.be.
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APPENDIX
or a complete list of participating DIVERGE
nvestigators, please see the online version of this article.
